ribonucleotide reductase / DNA polymerase (dCTP competition)

Class

nucleoside analog antimetabolite / DNA synthesis inhibitor

Pathway

DNA replication, chain termination

Ribonucleotide reductase (RNR) is the enzyme that converts ribonucleotides into the deoxyribonucleotides (dNTPs) required for DNA synthesis and repair. Because dividing cells consume large amounts of these building blocks, agents that interfere with dNTP supply or incorporation preferentially affect rapidly proliferating tissue, including many cancers. Gemcitabine is a cytidine nucleoside analog: once taken up by cells and converted to its active phosphate forms, it both inhibits ribonucleotide reductase, lowering the natural pool of deoxycytidine triphosphate (dCTP), and is itself incorporated into replicating DNA in place of dCTP by DNA polymerase. This substitution disrupts the growing DNA strand, arresting replication in a process referred to as chain termination. The combined effect of dNTP-pool depletion and direct DNA incorporation makes the analog more effective than either action alone, since reduced competition from natural dCTP increases the relative uptake of the drug into DNA. This mechanism underlies its broad use across solid tumors and hematologic malignancies characterized by high proliferative turnover. Reformulated versions of gemcitabine, delivered through altered drug-delivery systems such as lipid-based particles, aim to modify how the molecule is distributed and cleared in the body while preserving this same underlying antimetabolite mechanism.